Literature DB >> 28961306

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Gita Thanarajasingam1, Matthew J Maurer2, Umar Farooq3, Patrick B Johnston1, Carrie A Thompson1, Nabila N Bennani1, Stephen M Ansell1, Luis F Porrata1, William R Macon4, Sergei I Syrbu5, James R Cerhan2, Thomas M Habermann1, Brian K Link3, Thomas E Witzig1, Grzegorz S Nowakowski1.   

Abstract

Entities:  

Keywords:  central nervous system relapse; clinical trials; lymphomas

Mesh：

Year:  2017        PMID： 28961306      PMCID： PMC6107428          DOI： 10.1111/bjh.14922

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Prevention of CNS relapse in diffuse large B-cell lymphoma.

Authors:  Robert Kridel; Pierre-Yves Dietrich
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

2.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Authors:  Sophie Bernard; Lauriane Goldwirt; Sandy Amorim; Pauline Brice; Josette Brière; Eric de Kerviler; Samia Mourah; Hélène Sauvageon; Catherine Thieblemont
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

3.  Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.

Authors:  Anita Kumar; Ann Vanderplas; Ann S LaCasce; Maria A Rodriguez; Allison L Crosby; Eva Lepisto; Myron S Czuczman; Auayporn Nademanee; Joyce Niland; Leo I Gordon; Michael Millenson; Andrew D Zelenetz; Jonathan W Friedberg; Gregory A Abel
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

4.  Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Authors:  V Boehme; S Zeynalova; M Kloess; M Loeffler; U Kaiser; M Pfreundschuh; N Schmitz
Journal:  Ann Oncol       Date:  2006-10-03       Impact factor: 32.976

5.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

Authors:  Steven H Bernstein; Joseph M Unger; Michael Leblanc; Jonathan Friedberg; Thomas P Miller; Richard I Fisher
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

6.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

7.  Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Authors:  Anas Younes; Catherine Thieblemont; Franck Morschhauser; Ian Flinn; Jonathan W Friedberg; Sandy Amorim; Benedicte Hivert; Jason Westin; Jessica Vermeulen; Nibedita Bandyopadhyay; Ronald de Vries; Sriram Balasubramanian; Peter Hellemans; Johan W Smit; Nele Fourneau; Yasuhiro Oki
Journal:  Lancet Oncol       Date:  2014-07-17       Impact factor: 41.316

8.  Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Authors:  Grzegorz S Nowakowski; Betsy LaPlant; William R Macon; Craig B Reeder; James M Foran; Garth D Nelson; Carrie A Thompson; Candido E Rivera; David J Inwards; Ivana N Micallef; Patrick B Johnston; Luis F Porrata; Stephen M Ansell; Randy D Gascoyne; Thomas M Habermann; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2014-08-18       Impact factor: 44.544

9.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

10.  Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.

Authors:  D Villa; J M Connors; T N Shenkier; R D Gascoyne; L H Sehn; K J Savage
Journal:  Ann Oncol       Date:  2009-10-27       Impact factor: 32.976
  10 in total
  3 in total

Review 1.  SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.

Authors:  Jillian Simard; Mark Roschewski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2022-06-06

2.  Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

Authors:  Tarec Christoffer El-Galaly; Chan Yoon Cheah; Mette Dahl Bendtsen; Grzegorz S Nowakowski; Roopesh Kansara; Kerry J Savage; Joseph M Connors; Laurie H Sehn; Neta Goldschmidt; Adir Shaulov; Umar Farooq; Brian K Link; Andrés J M Ferreri; Teresa Calimeri; Caterina Cecchetti; Eldad J Dann; Carrie A Thompson; Tsofia Inbar; Matthew J Maurer; Inger Lise Gade; Maja Bech Juul; Jakob W Hansen; Staffan Holmberg; Thomas S Larsen; Sabrina Cordua; N George Mikhaeel; Martin Hutchings; John F Seymour; Michael Roost Clausen; Daniel Smith; Stephen Opat; Michael Gilbertson; Gita Thanarajasingam; Diego Villa
Journal:  Eur J Cancer       Date:  2018-02-21       Impact factor: 9.162

3.  CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Authors:  Ayed O Ayed; Annalisa Chiappella; Levi Pederson; Betsy R Laplant; Angela Giovanna Congiu; Gianluca Gaidano; Michele Spina; Alessandro Re; Federica Cavallo; Gerardo Musuraca; William R Macon; Thomas Witzig; Umberto Vitolo; Grzegorz S Nowakowski
Journal:  Blood Cancer J       Date:  2018-06-26       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.